Case Study Collaborations | Friends of Cancer Research

You are here

Case Study Collaborations

THE POWER OF COLLABORATION

Friends Annual Meeting

We are proud to host our yearly Annual Meeting with support from the American Association for Cancer Research, American Society of Clinical Oncology, and Susan G. Komen to address critical issues in the development of new oncology drugs. As of 2016, the Conference on Clinical Cancer Research has become the Friends Annual Meeting. From 2007 until 2015, Friends worked in conjunction with the Engelberg Center for Healthcare Reform at the Brookings Institution with support from Susan G. Komen for the Cure and the American Society of Clinical Oncology to host the annual meeting.

 

This meeting convenes a diverse group of experts in the cancer drug development field, including academic and clinical research centers, federal health and regulatory agencies, patient advocacy organizations, and the private sector to develop practical, consensus-driven solutions to critical challenges in the development of drugs for cancer.

 

The meeting emphasizes outcomes, and many of the panels have led to improvements in cancer care, including:

  • The 2012 passage of the Advancing Breakthrough Therapies for Patients Act
  • The development of Lung-MAP
  • The creation of the 2010 Guidance for FDA on how to test novel drugs in combination

 

In addition to the items listed above, other outcomes from the Friends Annual Meeting include:

2016

 

2015

 

2014

 

2013

 

2012

 

2011

 

2010

 

2009

 

2008

 

Other partners for the Annual Meeting include:

  • Cancer Information and Support Network
  • CDER, FDA
  • Clinical Investigation Branch, NCI
  • Columbia University Medical Center
  • Dana-Farber Cancer Institute
  • FDA Office of Hematology and Oncology Products
  • Fight Colorectal Cancer
  • Foundation Medicine
  • Fred Hutchinson Cancer Center
  • Gemini Group
  • Marti Nelson Cancer Foundation
  • Massachusetts General Hospital Cancer Center
  • Mayo Clinic
  • MD Anderson Cancer Center
  • Medical University of South Carolina
  • Melanoma Research Alliance
  • Office of Biostatistics, FDA
  • UC Davis Cancer Center
  • University of Chicago
  • University of North Carolina, Chapel Hill
  • Yale Cancer Center

A Blueprint for Drug/Diagnostic Co-development

Friends has partnered with Alexandria Real Estate Equities, Inc. for the last few years to host the series A Blueprint for Drug/Diagnostic Co-development. This summit brings together researchers, regulators, sponsors, and advocates to discuss possible approaches to improving and expediting development of diagnostics.

 

In addition to starting and continuing the conversation around this topic, white papers and articles have been developed in coordination with the summit. Those documents include:

 

Additional partners on the series include:

  • CDER, FDA
  • CDRH, FDA
  • Centers for Medicare and Medicaid Services (CMS)
  • Division of Cancer Treatment and Diagnosis, NCI
  • Fight Colorectal Cancer
  • Massachusetts General Hospital
  • Memorial Sloan-Kettering Cancer Center
  • National Cancer Institute (NCI)
  • Office of Clinical Pharmacology, FDA
  • Office of Hematology & Oncology Products, FDA
  • Washington University, School of Medicine

Lung-MAP

Lung-MAP is an unprecedented public-private collaboration among the National Cancer Institute, SWOG Cancer Research, the US Food and Drug Administration (FDA), the Foundation for the National Institutes of Health (FNIH), Foundation Medicine and several lung cancer advocacy organizations. First proposed at the 2012 Friends Annual Meeting, the final design was announced at the 2013 Annual Meeting, with the trial itself being in operation since 2014. As of September 2017, Lung-MAP is operating at more than 700 sites across the country.

 

Additional partners for Lung-MAP include:

  • Addario Lung Cancer Foundation
  • American Cancer Society
  • American Lung Association
  • Fred Hutchinson Cancer Center
  • Free to Breathe
  • Lung Cancer Alliance
  • Lung Cancer Foundation of America
  • LUNGevity Foundation
  • MD Anderson Cancer Center
  • UC Davis Cancer Center
  • Uniting Against Lung Cancer
  • Yale Cancer Center

Breakthrough Therapy Follow-Up

Since moving the breakthrough therapy designation from concept to reality in 2012, Friends has been instrumental in continuing to improve upon the designation and process.

Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events

In the last year, Friends has started work with University of North Carolina – Chapel Hill, FDA, NCI, Brookings Institution, and Cancer Information and Support Network on developing a tool to measure symptomatic adverse events related to cancer treatment from the patient perspective. This tool is called Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Additional Organizations Friends Partners With

  • Alexandria Real Estate Equities, Inc., Alexandria Venture Investments
  • American Association for Cancer Research
  • American Cancer Society
  • American Society of Clinical Oncology
  • Arizona State University
  • Association of American Cancer Institutes
  • Battelle Memorial Institute
  • Deerfield Management
  • GMMB
  • Mayer Brown LLP
  • Prevent Cancer Foundation
  • RCYMedicine
  • Research!America
  • The Sherry Lansing Foundation
  • The Weizmann Institute of Science


 

BECOME PART OF THE SOLUTION